在患有"隔离"透心性心力衰竭和透心功能障碍的患者中,系统性异常的进展
Cheuk-Man Yu1, Hong Lin, Hua Yang
1Division of Cardiology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong. cmyua@hkucc.hku.hk
Circulation
|March 13, 2002
概括
扩张性心力衰竭 (DHF) 经常与静心功能障碍并存,挑战了传统的诊断标准. 组织多普勒成像显示DHF患者微妙的缩异常,表明心力衰竭的谱.
科学领域:
- 心脏病学 心脏病学
- 心声回声扫描 (Echocardiography) 是一种心声回声扫描.
- 心脏衰竭病理生理学 病理生理学
背景情况:
- 扩张性心力衰竭 (DHF) 的诊断依赖于排除静脉缩功能障碍.
- 50%的射出分数 (EF) 截止值可能不足以准确诊断DHF.
- 据怀疑,缩功能障碍在DHF患者中很常见.
研究的目的:
- 用组织多普勒成像来调查被诊断为DHF的患者的缩异常的存在和程度.
- 评估心肌动脉速度在区分心力衰竭亚型中的诊断效用.
主要方法:
- 用组织多普勒成像对339名受试者进行心声谱,包括患有静心性心力衰竭 (SHF),大发性心力衰竭 (DHF),隔离性腹功能障碍 (DD) 的患者和正常对照者.
- 使用标准化细分模型分析了区域心肌速度曲线 (S(M) 和E(M)).
- 为了预测缩功能障碍,建立了平均S(M) 的值.
主要成果:
- 与对照组相比,患有SHF,DHF和DD的患者表现出明显较低的峰值区域心肌缩 (S(M)) 和早期心肌缩 (E(M)) 心肌速度.
- 在所有疾病组中,平均S (M) 和E (M) 值显著降低,SHF
- 平均S(M) 为4.4厘米/秒预测缩功能障碍在92%的SHF,52%的DHF和14%的DD患者中.
结论:
- 组织多普勒成像在以前被诊断为DHF和孤立DD的患者中发现了缩异常.
- 这些发现表明心力衰竭中缩和腹功能障碍的共同共存.
- 心力衰竭可能代表严重程度的频谱,涉及缩和透缩功能障碍.
相关概念视频
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...